Clinical Trial Update: Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating potential drug-drug interactions between tivantinib (ARQ 197) and five concomitant medicines in cancer patients with solid tumors. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Caffeine (caffeine)
• DIGOXIN (Digoxin)
• Midazolam (Midazolam)
• Omeprazole (Omeprazole)
• Warfarin (warfarin)
• tivantinib (tivantinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED